[In vitro drug sensitivity testing and chemotherapy of lung cancer].
100 lung cancer operated fresh specimens were collected for in vitro drug sensitivity testing, most of them were NSCLC. Those drugs were MMC(M), ADM(A), PDD(P) and VCR(O). 42% of them were sensitive to 2-4 drugs, but 39% were not sensitive to any of the 4 drugs, the sensitive rate of ADM was higher, 41%, MMC, VCR, and PDD were 37% and 32% respectively, but with no statistical meaning. There were 9 sensitive chemotherapy combination, MAPO combination was the highest, 73.8% of the specimens was sensitive to ADM and PDD, 73.8% of the combination included MMC. The in vitro sensitive drugs and sensitive rate were corresponded to the response rate on NSCLC clinically. As above-mentioned, it convinces us that in vitro drugs sensitivity may be meaningful for the design of combination chemotherapy regimen and developing new drugs for lung cancer.
Liao
M L
ML
Chest Dept., Shanghai Chest Hospital.
D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002283:Carcinoma, Bronchogenic / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014750:Vincristine / Q000494:pharmacology
D016685:Mitomycin; D014750:Vincristine; D004317:Doxorubicin; D002945:Cisplatin